No Data
Avidity Biosciences (RNA) Receives a Buy From TD Cowen
Avidity Biosciences: Advancing Clinical Programs With Strategic Focus and Growth Potential
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Avidity Biosciences to Participate in Upcoming Investor Conference
RBC Initiates Avidity Biosciences at Outperform, Speculative Risk With $67 Price Target
RBC Capital Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $67